Form 4: Equillium COO Sells Shares Under 10b5-1 Plan

Equillium's Senior Vice President and COO, Christine Zedelmayer, exercised stock options and subsequently sold 120,312 shares of common stock as part of a pre-arranged 10b5-1 trading plan.

Summary

• Christine Zedelmayer, Senior Vice President and COO of Equillium, Inc. (EQ), executed a transaction on March 13, 2026.
• She acquired 120,312 shares of common stock by exercising employee stock options at a price of $0.785 per share.
• Concurrently, she sold 120,312 shares of common stock at a weighted average price of $2.5003 per share.
• The sale was conducted under a Rule 10b5-1 trading plan adopted on August 27, 2025.
• Following these transactions, Christine Zedelmayer beneficially owns 62,586 shares of common stock directly and 54,688 derivative securities (employee stock options).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While it's an insider sale, its execution under a pre-arranged 10b5-1 plan mitigates concerns about opportunistic selling, making it a routine compensation-related transaction.

Positives

• The executive exercised options, indicating a realization of value from her compensation.
• The exercise price of $0.785 per share is significantly lower than the sale price of $2.5003, indicating a profitable transaction for the executive.

Negatives

• An insider sale, even if pre-planned, reduces the executive's direct equity stake in the company.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under a Rule 10b5-1 plan, are common occurrences. While a sale reduces an executive's direct holdings, a pre-arranged plan suggests the transaction is not based on new, material non-public information, distinguishing it from opportunistic selling.

Comparison to Industry Standards

• Insider sales under 10b5-1 plans are a standard practice for executives to diversify their holdings and manage liquidity without violating insider trading rules.
• This transaction aligns with typical executive compensation and wealth management strategies seen across the biotech and pharmaceutical sectors, where stock options are a significant component of remuneration.

Related Party Transactions

• The transaction involves Christine Zedelmayer, a Senior Vice President and COO of Equillium, Inc., exercising stock options and selling shares of the company, which is a standard related party transaction for executive compensation.

Stakeholder Impact

• Shareholders: The sale slightly increases the float but is unlikely to have a significant impact given it's a pre-planned transaction.
• Employees: No direct impact on employees.
• Management: The transaction represents a realization of value for the executive's compensation.

Key Dates

Recommendation

The transaction is a routine insider sale executed under a pre-arranged 10b5-1 plan, which typically does not signal a change in the company's fundamentals or future prospects. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Equillium, EQ, Christine Zedelmayer, Insider Trading, Form 4, Stock Option Exercise, Share Sale, 10b5-1 Plan, Executive Compensation